Novo Crashes 20% After New Obesity Drug Misses Forecasts. Lilly, Viking, Amgen Jump. - Investor's Business Daily
- Novo Crashes 20% After New Obesity Drug Misses Forecasts. Lilly, Viking, Amgen Jump. Investor's Business Daily
- Novo Nordisk Shares Plunge After New Obesity Shot Disappoints The Wall Street Journal
- Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results Yahoo Finance
- Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps CNBC
- Novo Nordisk Falls Most on Record After New Weight Drug Disappoints Bloomberg